Goldman Sachs' Marco Argenti said businesses need to integrate company culture into AI agents. The tech industry has mostly focused on the "specialization of expertise," he said. AI agents — AI ...

Goldman Sachs analyst Lisa Yang resumed coverage of Naspers (NPSNY) with a Buy rating and ZAR 6,144 price target The company represents a profitable growth and value crystallization opportunity at ...

Goldman Sachs resumed coverage of Prosus (PROSY) with a Buy rating and EUR 56 price target Prosus presents an attractive fundamental growth and profitability outlook through its ownership of ...

The round was led by a division of investment bank Goldman Sachs. Other investors in the round included venture capital firms Vertex Ventures Israel, Grove Ventures and Alive Israel HealthTech Fund.

Goldman Sachs reiterates Buy on Waystar, sets $52 price target despite post-earnings dip. Analyst sees FY25 growth concerns but expects upside from beat-and-raise trends and deleveraging.

On March 3, 2025, Goldman Sachs Asset Management announced that veteran manager Steven Barry will retire at the end of 2025 and will step off Goldman Sachs Strategic Growth at the end of June 2025.

Diamond has comanaged this strategy since the end of 2002, the same year he joined Goldman Sachs Asset Management after nine years with Prudential's muni group. The firm officially appointed Yeh ...

2-Year U.S. Treasury Note Continuous Contract $103.516 0.027 0.03% 5-Year U.S. Treasury Note Continuous Contract $108.000 0.078 0.07% 10-Year U.S. Treasury Note Continuous Contract $111.141 0.141 ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Sachs in an email told Reuters he had been appointed Prabowo's special adviser. "And in this capacity (I) will serve on the advisory board of Danantara," he said. "My work is entirely voluntary ...

and worked for seven-and-a-half years at Goldman Sachs & JBWere in Melbourne, predominantly on the Healthcare/Biotech and Portfolio Strategy Research teams.